BLTE Belite Bio Inc

FDA Catalyst Company
12.68
+0.22  (+2%)
Previous Close 12.46
Open 12.18
52 Week Low 8.8
52 Week High 17.5
Market Cap $305,528,620
Shares 24,095,317
Float 24,095,317
Enterprise Value $288,184,619
Volume 2,684
Av. Daily Volume 332,950
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Latest News

  1. SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases such as dry AMD and Stargardt disease, and metabolic diseases, today announced that the underwriters of its previously announced initial public offering (the "IPO") have exercised in part their over-allotment option to purchase an additional 772,091 American Depositary Shares (the "ADS") of the Company at the IPO price of $6.00 per ADS. Each ADS represents one ordinary share of Belite.

    After giving effect to the partial exercise of the over-allotment option, Belite has issued and sold a total of 6,772,091 ADSs in the IPO, for total gross…

    View Full Article
    • LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjects
    • A trend for stabilized or improved visual acuity was observed
    • Observed adverse events were anticipated based on the mechanism of LBS-008 action
    • STGD1 subjects from the Phase 1b study are now participating in the 2-year, Phase 2 extension

    SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (the "Company") (NASDAQ:BLTE),  a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, such as atrophic Age-related Macular Degeneration (dry AMD) and Stargardt disease (STGD1), and metabolic diseases, presented interim results of a Phase 1b/2 study of LBS-008 in adolescent…

    View Full Article
  2. SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases such as dry AMD and Stargardt disease, and metabolic diseases, today announced the closing of its previously announced initial public offering of 6 million American Depositary Shares (ADSs) at a public offering price per ADS of $6.00. Each ADS represents one ordinary share of Belite. In addition, Belite has granted the underwriters a 30-day option to purchase an additional 900,000 ADSs at the initial public offering price, less the underwriting discounts and commissions.

    Lin Bioscience International Ltd., our principal shareholder…

    View Full Article
    • LBS-008 (aka Tinlarebant) is the Company's orally administered tablet for the treatment of Stargardt disease (STGD1)
    • There are currently no approved treatments for STGD1
    • A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing
    • LBS-008, the Company's lead asset, has been granted rare pediatric disease designation in the U.S. and orphan drug designation in the U.S. and Europe
    • Approximately 30,000 patients in the U.S. suffer from STGD1

    SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (the "Company") (NASDAQ:BLTE),  a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, such as atrophic Age-related Macular Degeneration (dry AMD…

    View Full Article
View All Belite Bio Inc News